AIM IMMUNOTECH INC. Cost of Revenue
AIM IMMUNOTECH INC. (AIM) reported Cost of Revenue of $353.00 thousand for the 3-month period ending 2015-09-30, per its 10-Q filed 2015-11-16.
Discontinued › Expense Statement
us-gaap:CostOfRevenue · last filed 2015-11-16
- AIM IMMUNOTECH INC. cost of revenue for the quarter ending 2015-09-30 was $353.00K, a 15.36% increase year-over-year.
- AIM IMMUNOTECH INC. cost of revenue for the quarter ending 2015-06-30 was $507.00K, a 72.45% increase year-over-year.
- AIM IMMUNOTECH INC. cost of revenue for the quarter ending 2015-03-31 was $372.00K, a 15.17% increase year-over-year.
- AIM IMMUNOTECH INC. cost of revenue for the quarter ending 2014-12-31 was $328.00K, a 110.26% increase year-over-year.
- AIM IMMUNOTECH INC. cost of revenue for fiscal 2014 was $1.25M, a 1.38% increase from fiscal 2013.
- AIM IMMUNOTECH INC. cost of revenue for fiscal 2013 was $1.23M, a 37.96% decline from fiscal 2012.
- AIM IMMUNOTECH INC. cost of revenue for fiscal 2012 was $1.99M, a 90.70% increase from fiscal 2011.
- AIM IMMUNOTECH INC. cost of revenue for fiscal 2011 was $1.04M, a 22.22% decline from fiscal 2010.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2015-09-30 | $353.00K 10-Q · filed 2015-11-16 | $860.00K derived: sum of 2 quarters · filed 2015-11-16 | $1.23M 10-Q · filed 2015-11-16 | $1.56M derived: sum of 4 quarters · filed 2015-11-16 |
| 2015-06-30 | $507.00K 10-Q · filed 2015-08-12 | $879.00K 10-Q · filed 2015-08-12 | $1.21M derived: sum of 3 quarters · filed 2015-08-12 | $1.51M derived: sum of 4 quarters · filed 2015-11-16 |
| 2015-03-31 | $372.00K 10-Q · filed 2015-05-12 | $700.00K derived: sum of 2 quarters · filed 2015-05-12 | $1.01M derived: sum of 3 quarters · filed 2015-11-16 | $1.30M derived: sum of 4 quarters · filed 2015-11-16 |
| 2014-12-31 | $328.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-19 | $634.00K derived: sum of 2 quarters · filed 2015-11-16 | $928.00K derived: sum of 3 quarters · filed 2015-11-16 | $1.25M 10-K · filed 2015-03-19 |
| 2014-09-30 | $306.00K 10-Q · filed 2015-11-16 | $600.00K derived: sum of 2 quarters · filed 2015-11-16 | $923.00K 10-Q · filed 2015-11-16 | $1.08M derived: sum of 4 quarters · filed 2015-11-16 |
| 2014-06-30 | $294.00K 10-Q · filed 2015-08-12 | $617.00K 10-Q · filed 2015-08-12 | $773.00K derived: sum of 3 quarters · filed 2015-08-12 | $1.02M derived: sum of 4 quarters · filed 2015-08-12 |
| 2014-03-31 | $323.00K 10-Q · filed 2015-05-12 | $479.00K derived: sum of 2 quarters · filed 2015-05-12 | $731.00K derived: sum of 3 quarters · filed 2015-05-12 | $1.37M derived: sum of 4 quarters · filed 2015-05-12 |
| 2013-12-31 | $156.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-19 | $408.00K derived: sum of 2 quarters · filed 2015-03-19 | $1.04M derived: sum of 3 quarters · filed 2015-03-19 | $1.23M 10-K · filed 2015-03-19 |
| 2013-09-30 | $252.00K 10-Q · filed 2014-11-07 | $887.00K derived: sum of 2 quarters · filed 2014-11-07 | $1.08M 10-Q · filed 2014-11-07 | $1.59M derived: sum of 4 quarters · filed 2015-03-19 |
| 2013-06-30 | $635.00K 10-Q · filed 2014-08-08 | $826.00K 10-Q · filed 2014-08-08 | $1.34M derived: sum of 3 quarters · filed 2015-03-19 | $2.33M derived: sum of 4 quarters · filed 2015-03-19 |
| 2013-03-31 | $191.00K 10-Q · filed 2014-05-09 | $704.00K derived: sum of 2 quarters · filed 2015-03-19 | $1.69M derived: sum of 3 quarters · filed 2015-03-19 | $1.90M derived: sum of 4 quarters · filed 2015-03-19 |
| 2012-12-31 | $513.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-19 | $1.50M derived: sum of 2 quarters · filed 2015-03-19 | $1.71M derived: sum of 3 quarters · filed 2015-03-19 | $1.99M 10-K · filed 2015-03-19 |
| 2012-09-30 | $988.00K 10-Q · filed 2013-11-08 | $1.20M derived: sum of 2 quarters · filed 2013-11-08 | $1.48M 10-Q · filed 2013-11-08 | $1.91M derived: sum of 4 quarters · filed 2014-03-14 |
| 2012-06-30 | $208.00K 10-Q · filed 2013-08-09 | $488.00K 10-Q · filed 2013-08-09 | $917.00K derived: sum of 3 quarters · filed 2014-03-14 | $1.13M derived: sum of 4 quarters · filed 2014-03-14 |
| 2012-03-31 | $280.00K 10-Q · filed 2013-05-08 | $709.00K derived: sum of 2 quarters · filed 2014-03-14 | $926.00K derived: sum of 3 quarters · filed 2014-03-14 | $1.13M derived: sum of 4 quarters · filed 2014-03-14 |
| 2011-12-31 | $429.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14 | $646.00K derived: sum of 2 quarters · filed 2014-03-14 | $850.00K derived: sum of 3 quarters · filed 2014-03-14 | $1.04M 10-K · filed 2014-03-14 |
| 2011-09-30 | $217.00K 10-Q · filed 2012-11-02 | $421.00K derived: sum of 2 quarters · filed 2012-11-02 | $614.00K 10-Q · filed 2012-11-02 | $1.31M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-06-30 | $204.00K 10-Q · filed 2012-08-08 | $397.00K 10-Q · filed 2012-08-08 | $1.09M derived: sum of 3 quarters · filed 2013-03-18 | $1.27M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-03-31 | $193.00K 10-Q · filed 2012-05-07 | $885.00K derived: sum of 2 quarters · filed 2013-03-18 | $1.07M derived: sum of 3 quarters · filed 2013-03-18 | $1.39M derived: sum of 4 quarters · filed 2013-03-18 |
| 2010-12-31 | $692.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $873.00K derived: sum of 2 quarters · filed 2013-03-18 | $1.20M derived: sum of 3 quarters · filed 2013-03-18 | $1.34M 10-K · filed 2013-03-18 |
| 2010-09-30 | $181.00K 10-Q · filed 2011-11-09 | $509.00K derived: sum of 2 quarters · filed 2011-11-09 | $649.00K 10-Q · filed 2011-11-09 | |
| 2010-06-30 | $328.00K 10-Q · filed 2011-08-05 | $468.00K 10-Q · filed 2011-08-05 | ||
| 2009-12-31 | $584.00K 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |